{"organizations": [], "uuid": "e5ee5eb4f027974db907e83c139e38d14d3d7ec4", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/markets/bonds", "section_title": "Rates ", "url": "https://www.reuters.com/article/brief-ligand-pharmaceuticals-announces-p/brief-ligand-pharmaceuticals-announces-proposed-offering-of-650-mln-of-convertible-senior-notes-idUSASC0A2OS", "country": "US", "domain_rank": 408, "title": "BRIEF-Ligand Pharmaceuticals Announces Proposed Offering Of $650 Mln Of Convertible Senior Notes", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.049, "site_type": "news", "published": "2018-05-17T04:56:00.000+03:00", "replies_count": 0, "uuid": "e5ee5eb4f027974db907e83c139e38d14d3d7ec4"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-ligand-pharmaceuticals-announces-p/brief-ligand-pharmaceuticals-announces-proposed-offering-of-650-mln-of-convertible-senior-notes-idUSASC0A2OS", "ord_in_thread": 0, "title": "BRIEF-Ligand Pharmaceuticals Announces Proposed Offering Of $650 Mln Of Convertible Senior Notes", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "ligand pharmaceuticals inc", "sentiment": "negative"}, {"name": "brief-ligand pharmaceuticals", "sentiment": "negative"}, {"name": "ligand", "sentiment": "negative"}, {"name": "ligand pharmaceuticals", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 16 (Reuters) - Ligand Pharmaceuticals Inc:\n* LIGAND ANNOUNCES PROPOSED OFFERING OF $650 MILLION OF CONVERTIBLE SENIOR NOTES\n* LIGAND PHARMACEUTICALS INC - INTENDS TO OFFER $650 MILLION AGGREGATE PRINCIPAL AMOUNT OF CONVERTIBLE SENIOR NOTES DUE 2023 IN A PRIVATE OFFERING\n* LIGAND PHARMACEUTICALS - INTENDS TO USE PORTION OF NET PROCEEDS FROM OFFERING OF NOTES TO PAY COST OF CERTAIN CONVERTIBLE NOTE HEDGE TRANSACTIONS\n* LIGAND PHARMACEUTICALS - TO USE PROCEEDS FROM OFFERING ALSO TO BUYBACK UP TO $50 MILLION OF COâ€™S SHARES FROM BUYERS OF NOTES IN PRIVATELY NEGOTIATED DEALS Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-17T04:56:00.000+03:00", "crawled": "2018-05-17T01:37:21.000+03:00", "highlightTitle": ""}